eatured Research
from universities, journals, and other organizations
Reviving drugs with anti-stroke potential, minus side effects
Date:
February 27, 2015
Source:
Emory Health Sciences
Summary:
Scientists have found NMDA receptor antagonists that can limit damage to the brain in animal models of stroke, apparently without the pronounced side effects seen with similar drugs. Now researchers have found a potential path around this obstacle, they report.
Schematic representation of the NMDA receptor complex. NMDA receptor antagonists can have beneficial effects in animal models of stroke, but also have pronounced side effects such as disorientation and hallucinations.
Credit: Image courtesy of Emory Health Sciences
In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations.
Related Articles
Now researchers have found a potential path around this obstacle. The results were published in Neuron.
"We have found neuroprotective compounds that can limit damage to the brain during ischemia associated with stroke and other brain injuries, but have minimal side effects," says senior author Stephen Traynelis, PhD, professor of pharmacology at Emory University School of Medicine.
"These compounds are most active when the pH is lowered by biochemical processes associated with injury of the surrounding tissue. This is a proof of concept study that shows this mechanism of action could potentially be exploited clinically in several conditions, such as stroke, traumatic brain injury and subarachnoid hemorrhage."
In a mouse model of ischemic stroke, a NMDA receptor antagonist called 93-31 can reduce the volume of damaged brain tissue by more than half, researchers found. At the same time, giving mice 93-31 does not seem to lead to the side effects seen with other NMDA receptor antagonists.
The drugs phencyclidine (also known as PCP) and ketamine are NMDA receptor antagonists; their ability to block all subtypes of NMDA receptors is thought to account for their psychoactive side effects. NMDA receptors are abundant on the surfaces of brain cells and play key roles in healthy processes such as memory formation.
In brain tissue affected by stroke or traumatic injury, the environment becomes more acidic because of the lack of oxygen and the buildup of metabolites such as lactic acid. In addition, NMDA receptors get overstimulated by an increase in the neurotransmitter glutamate -- enough to kill cells. Researchers reasoned that NMDA receptor antagonists whose activity is dependent on acidic conditions should, at the right dose, be active only in the injured areas of the brain.
To identify the new pH-dependent drugs, Emory pharmacologists led by Traynelis and Ray Dingledine, PhD collaborated with chemists Dennis Liotta, PhD and James Snyder, PhD. The co-first authors of the Neuron paper are pharmacology instructor Hongjie Yuan PhD, chemistry postdoctoral fellow Gordon Wells, PhD and Scott Myers, PhD, director of drug discovery at Atlanta-based pharmaceutical company NeurOp.
In medicinal chemistry terms, 93-31 is ten times more potent at pH 6.9, typical for ischemic tissue with an insufficient blood supply, than at pH 7.6, close to the value for healthy brain tissue.
In collaboration with Katherine Nicholson, PhD at Virginia Commonwealth University, the researchers tested 93-31 on mice trained to press a lever when they detect low levels of PCP. When researchers substituted 93-31 for PCP, the mice did not perceive 93-31's subjective effects to be similar enough to PCP's to respond by pressing levers in the same way.
Doses of 93-31 that had a positive effect in the stroke model did not seem to impair coordination or motor function. The mice could still hold onto a turning rod, in contrast with mice dosed with other NMDA receptor antagonists.
The research that led to 93-31's identification has been a platform for further drug discovery efforts by NeurOp, according to the company's CEO, Barney Koszalka, PhD. However, 93-31's pharmaceutical profile may not be optimal for further development, he says. In mouse experiments in the Neuron paper, 93-31 was either injected directly into the brain or into the body cavity.
NeurOp is developing a related candidate drug as a potential preventive measure for people who experience subarachnoid hemorrhage, because they have a high risk of a secondary stroke-like event for days after the initial hemorrhage. NeurOp is completing safety studies and is planning to file an Investigational New Drug application with the FDA later in 2015.
"We are taking an analogue of the compound identified in the Neuron paper forward as a post-surgical treatment for individuals that have suffered a subarachnoid hemorrhage," Koszalka says. "The pH boost we see with this series of subunit specific NMDA modulators is expected to provide an additional safety advantage."
Story Source:
The above story is based on materials provided by Emory Health Sciences. Note: Materials may be edited for content and length.
Journal Reference:
- Hongjie Yuan, Scott J. Myers, Gordon Wells, Katherine L. Nicholson, Sharon A. Swanger, Polina Lyuboslavsky, Yesim A. Tahirovic, David S. Menaldino, Thota Ganesh, Lawrence J. Wilson, Dennis C. Liotta, James P. Snyder, Stephen F. Traynelis. Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects. Neuron, 2015; DOI:10.1016/j.neuron.2015.02.008
Cite This Page:
Share This
More From ScienceDaily
More Mind & Brain News
Friday, February 27, 2015
Featured Research
from universities, journals, and other organizations
Research of Plain Wren Duets Could Help Further Understand Fundamentals of Conversation
Feb. 27, 2015 — Known for their beautiful singing duets, plain wrens of Costa Rica perform precise phrase-by-phrase modifications to the duration between two consecutive phrases, achieving careful coordination as ... full story
- Wren Duets Illuminate Fundamentals of ...
- Introverts Prefer Mountains
- MS: New Compounds Protect Nervous System
- Drugs With Anti-Stroke Potential, No Side Effects
- TBI: More Studies On Possible Blood Biomarker
- MS: Is There MD-Industry Conflict of Interest?
- Aggressive Boys Develop Into Stronger Teens?
- Unconscious Memory System: Theory Challenged
- Mom's Stress Ups Infants' Secondhand Smoke Risk
- Left or Right? The Brain Knows Before You Move
newer top stories | older top stories
Related Stories
Unprecedented Structural Insights: NMDA Receptors Can Be Blocked to Limit Neurotoxicity
Jan. 22, 2014 — Structural biologists have obtained important scientific results likely to advance efforts to develop new drugs targeting NMDA receptors in the ... full story
Strange & Offbeat Stories
Health & Medicine
- Zombie Outbreak? Statistical Mechanics Reveals the Ideal Hideout; And Informs Real Disease Modeling
- Neurons Controlling Appetite Made from Skin Cells
- Living in Genetic Comfort Zone: How to Avoid Influence of Genetic Variation
- Could Squirmy Livestock Dent Africa's Protein Deficit?
- Sewage Provides Insight Into Human Microbiome
Mind & Brain
- Neurons That Help Predict What Another Individual Will Do Identified
- Bumblebees Make False Memories Too
- Blockbusters: Can EEGs Predict a Movie's Success Better Than Surveys?
- Sensor-Packed Smartphones Can Read Your Mood, Guard Your Data, and Wreak Havoc in the Wrong Hands
- Neuroscientists Literally Change the Way We Think: Advantages of a Wandering Mind
Living & Well
- Why a Latte Is Less Likely to Spill Than a Coffee
- Sauna Use Associated With Reduced Risk of Cardiac, All-Cause Mortality
- Can You Judge a Man by His Fingers? Link Between Relative Lengths of Index and Ring Fingers in Men and Behavior Towards Women
- Women Seek Greater Variety in Men and Consumer Products Near Ovulation
- People Value Resources More Consistently When They Are Scarce
In Other News
... from NewsDaily.com
Science News
- NASA resolves issue with spacesuit helmet water leak
- Monsanto says GM corn trial in final stage in India
- U.S. rocket launch pad repair set to halt in funding spat
- Stone Age Britons imported wheat in shock sign of sophistication
- Playing physics: Student builds Lego Large Hadron Collider
Health News
- Doctors with bad news seen as less compassionate
- China imposes trade restrictions on Canadian beef
- Younger men more bothered after prostate cancer treatment
- Three infected with measles at Las Vegas seafood restaurant
- Actavis hormonal contraceptive device wins FDA approval
Environment News
- Earthquake shakes Guatemala City: Reuters witness
- Environmental group sues U.S. EPA over monarch butterfly demise
- Texas snowstorm snarls transport, cancels nearly 600 flights
- Third calf born to endangered killer whale population in U.S. Pacific Northwest
- Chile dairy farmers sound alarm over drought in south
Technology News
- Google submits plans to expand Silicon Valley headquarters
- White House releases draft bill to protect consumer data privacy
- Oracle sues Oregon officials in healthcare website dispute
- Cook says Apple Watch will replace car keys: Telegraph
- Sacked Sanofi boss joins PureTech board
No comments:
Post a Comment
Please leave a comment-- or suggestions, particularly of topics and places you'd like to see covered